22 March 2018

TIKOMED PRESENTS IBSOLVMIR AT BIO EUROPE

IBsolvMIR is TikoMed’s original project addressed at alleviating the ”Instant Blood Mediated Inflammatory Reaction” that occurs when transplanted cells enter the bloodstream and come in contact with blood. IBsolvMIR has been documented to be a very safe drug and has shown efficacy in a Phase 2 study. TikoMed will now focus efforts on partnering strategy in order to bring the drug to the market.
At BIO Europe, Adam Bruce, founder of TikoMed presented development status and partner strategy for the project.

DATE
TBA

TIME
TBA

VENUE
TBA

OTHER NEWS

2 November 2018
First patient treated with ILB in TIKOMED’s clinical trial for ALS
Viken, November 2nd, 2018 — TIKOMED, a specialty pharmaceutical company focused on developing therapeutics for…
Read More
20 August 2018
TIKOMED to initiate ALS clinical trial for which the UK Medicines and Healthcare products Regulatory Agency has granted permission
Viken, August 20th, 2018 — TIKOMED, a specialty pharmaceutical company focused on developing therapeutics for…
Read More
14 August 2018
TIKOMED Announce Start of ALS Study at Sahlgrenska University Hospital
VIKEN, Sweden, August 14, 2018 – ​TIKOMED, a specialty pharmaceutical company focused on developing therapeutics…
Read More
SEE MORE